Royalty Finance
As royalty financings and monetizations grow in scale and demand, our lawyers serve as trusted partners to companies and investors in their most important domestic and international royalty-based transactions. We offer clients a deep understanding of the market forces, major players, and complex considerations in this critical financing area.
Our team is a steady guide for pharmaceutical and biotechnology, medical device, healthcare, energy, and technology companies in unlocking the value of their royalty streams through sales, financings, and structured transactions. On the investor side, we work in close partnership with private equity funds, specialty finance firms, institutional investors, and asset managers to overcome obstacles and take advantage of the opportunities that royalty-based lending, royalty monetization, and synthetic royalty transactions present.
Comprehensive Scope
Tapping a talent pool of lawyers across our global, full-service platform, our team works in lockstep with our firm’s market-leading life sciences transactions, finance, tax, and intellectual property lawyers to structure transactions that best suit each client’s unique objectives.
We structure and negotiate a broad spectrum of royalty-backed transactions, including:
- Traditional third-party monetizations
- Synthetic monetizations
- Royalty-based debt
- Product funding
- Royalty-based financings
- Royalty sharing agreements
Our command of the issues and worldwide capabilities mean that we can address specific areas of concern such as IP asset, regulatory, bankruptcy and tax considerations and as well as the broader strategic implications arising in complex royalty-based transactions.